AU2017311666B2 - Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and NMDA receptor antagonist - Google Patents
Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and NMDA receptor antagonist Download PDFInfo
- Publication number
- AU2017311666B2 AU2017311666B2 AU2017311666A AU2017311666A AU2017311666B2 AU 2017311666 B2 AU2017311666 B2 AU 2017311666B2 AU 2017311666 A AU2017311666 A AU 2017311666A AU 2017311666 A AU2017311666 A AU 2017311666A AU 2017311666 B2 AU2017311666 B2 AU 2017311666B2
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- morpholin
- phenyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title claims abstract description 76
- 229940099433 NMDA receptor antagonist Drugs 0.000 title claims abstract description 61
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title claims abstract description 61
- 239000002469 receptor inverse agonist Substances 0.000 title claims abstract description 48
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims description 96
- 238000011282 treatment Methods 0.000 claims description 88
- 208000024827 Alzheimer disease Diseases 0.000 claims description 72
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 65
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical group Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 58
- 229960004640 memantine Drugs 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 33
- 229960003530 donepezil Drugs 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 208000010877 cognitive disease Diseases 0.000 claims description 25
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 229960000967 memantine hydrochloride Drugs 0.000 claims description 18
- LNXDUSQEXVQFGP-UHFFFAOYSA-N n-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1NC(=O)CN1CCOCC1 LNXDUSQEXVQFGP-UHFFFAOYSA-N 0.000 claims description 17
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 15
- LCPQCTBHZPMVFX-UHFFFAOYSA-N n-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide;dihydrochloride Chemical compound Cl.Cl.C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1NC(=O)CN1CCOCC1 LCPQCTBHZPMVFX-UHFFFAOYSA-N 0.000 claims description 15
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 14
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 13
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 13
- 201000002832 Lewy body dementia Diseases 0.000 claims description 13
- 229960004136 rivastigmine Drugs 0.000 claims description 13
- 201000000980 schizophrenia Diseases 0.000 claims description 13
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 229960003135 donepezil hydrochloride Drugs 0.000 claims description 12
- 229960003980 galantamine Drugs 0.000 claims description 12
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 12
- 201000004810 Vascular dementia Diseases 0.000 claims description 11
- 201000010374 Down Syndrome Diseases 0.000 claims description 10
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 10
- 208000016620 Tourette disease Diseases 0.000 claims description 10
- WRSZOMBMEGHKOJ-UHFFFAOYSA-N 2-morpholin-4-yl-n-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]acetamide Chemical compound C1CN(C(C)C)CCC1OC(C=C1)=CC=C1NC(=O)CN1CCOCC1 WRSZOMBMEGHKOJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- LWAJGASQEKHLCH-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid 2-morpholin-4-yl-N-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]acetamide Chemical compound OC(C(O)C(O)=O)C(O)=O.CC(C)N1CCC(CC1)Oc1ccc(NC(=O)CN2CCOCC2)cc1 LWAJGASQEKHLCH-UHFFFAOYSA-N 0.000 claims description 8
- HWVBCAJMEZQYSG-UHFFFAOYSA-N n-[4-(1-cyclopropylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide Chemical compound C=1C=C(OC2CCN(CC2)C2CC2)C=CC=1NC(=O)CN1CCOCC1 HWVBCAJMEZQYSG-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- QPDVQLMRYAGBDM-UHFFFAOYSA-N N-[4-(1-cyclopropylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide 2,3-dihydroxybutanedioic acid Chemical compound OC(C(O)C(O)=O)C(O)=O.O=C(CN1CCOCC1)Nc1ccc(OC2CCN(CC2)C2CC2)cc1 QPDVQLMRYAGBDM-UHFFFAOYSA-N 0.000 claims description 6
- 230000002500 effect on skin Effects 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 abstract description 14
- 108020003175 receptors Proteins 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 description 45
- 229940120402 donepezil and memantine Drugs 0.000 description 34
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 25
- 229960004373 acetylcholine Drugs 0.000 description 25
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 206010012289 Dementia Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 241000700157 Rattus norvegicus Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 9
- 229940125425 inverse agonist Drugs 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940044551 receptor antagonist Drugs 0.000 description 8
- 239000002464 receptor antagonist Substances 0.000 description 8
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- 229940126214 compound 3 Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 102100033639 Acetylcholinesterase Human genes 0.000 description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000013016 learning Effects 0.000 description 5
- 210000002442 prefrontal cortex Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- -1 Cyclopropylpiperidin-4-yloxy Chemical group 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011278 co-treatment Methods 0.000 description 3
- 210000005110 dorsal hippocampus Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 3
- 229960002024 galantamine hydrobromide Drugs 0.000 description 3
- 230000000848 glutamatergic effect Effects 0.000 description 3
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000001690 micro-dialysis Methods 0.000 description 3
- 230000003414 procognitive effect Effects 0.000 description 3
- 229960004323 rivastigmine tartrate Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 150000003892 tartrate salts Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 231100000491 EC50 Toxicity 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940077168 namzaric Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- BWRNWWSQZROEOA-UHFFFAOYSA-N 2-morpholin-4-ylacetamide Chemical compound NC(=O)CN1CCOCC1 BWRNWWSQZROEOA-UHFFFAOYSA-N 0.000 description 1
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100040405 Lysophosphatidic acid receptor 4 Human genes 0.000 description 1
- 101710149746 Lysophosphatidic acid receptor 4 Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019145 PO4.2H2O Inorganic materials 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000002253 acid Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 229940033872 namenda Drugs 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229940051845 razadyne Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000009151 sensory gating Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003135 vibrissae Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides histamine-3 receptor (H
Description
TRIPLE COMBINATION OF HISTAMINE-3 RECEPTOR INVERSE AGONISTS, ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONIST
FIELD OF THE INVENTION
The present invention relates to histamine-3 receptor (H3R) inverse agonists or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors (AChEIs) and N-Methyl-D-aspartate (NMDA) receptor antagonist. The present invention further relates to the use of the combination and the pharmaceutical composition containing the said combination in the treatment of cognitive disorders.
BACKGROUND OF INVENTION
Alzheimer’s disease (AD) is the most common cause of dementia worldwide. The exponential rise in the number of cases of AD in the past and the future projection over the next few decades is anticipated to result in great pressure on the social and health-care systems of developed and developing economies alike. AD also imposes tremendous emotional and financial burden to the patient’s family and community.
The current list of approved cognitive enhancing drugs for AD is not long and historically been focused on acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine). These drugs act by inhibiting the hydrolysis of acetylcholine (ACh) into acetate and choline by targeting acetylcholinesterase (AChE) enzyme. Increasing the ACh levels in the synapse can stimulate cholinergic receptors and promote memory function. Although acetylcholinesterase inhibitors (AChEIs) can temporarily delay the progression of cognitive decline in AD, their effects are modest. ACh being present both in the central and peripheral nervous system, AChEIs produce several undesirable side effects such as gastrointestinal disturbances, bradycardia and excessive salivation that are associated with an action on peripheral muscarinic cholinergic receptors (Expert Opinion on Drug Safety, 3, 2004, 425-440). The limitation of AChE inhibitor class of drugs is that they are poorly tolerated, their efficacy is not
WO 2018/033848
PCT/IB2017/054939 sustained and they require constant dose-titration as the disease progresses (Cochrane Database Systematic Reviews, 2006, CD005593) which lead to significant patient noncompliance. The incidence and the severity of these side effects increase with the dose amount and in general more pronounced at the 5 initiation of the treatment or after dose increase. Hence there is an unmet need of alternate therapy for treating cognition disorders.
The H3R is a G protein-coupled receptor (GPCR), mainly expressed in the anterior part of the cortex, hippocampus and the striatum. H3RS function as both autoreceptors and heteroreceptors. It modulates the synthesis and release of 10 several neurotransmitters which play an important role in cognition, mood and sensory gating. Preliminary literature reports suggest that H3R antagonists may have promising utility for the treatment of various CNS disorders including AD, schizophrenia, attention-deficit hyperactivity disorder (ADHD), epilepsy, narcolepsy, neuropathic pain and metabolic disorders. Antagonism of this receptor 15 by several investigational compounds has been shown to improve learning and memory in animal models.
Since blocking H3R modulates histaminergic and cholinergic activity, one might expect H3R inverse agonist to complement and/or augment cognitive function of AChEIs. This may in turn help to reduce side effects with better 20 patient compliance and thus can be administered over a long period.
The glutamatergic system is also involved in learning and memory and is a target for treatment of Alzheimer’s disease. Memantine, another approved treatment for Alzheimer’s disease, acts on the glutamatergic system by inhibiting NMDA receptor under conditions of excess stimulation. It may act to protect 25 glutamate neurons from excessive glutamate stimulation, while increasing the signal to noise ratio. It is known that glutamate neurons have synaptic connections on cholinergic neurons in brain areas associated with learning and memory.
Since the cause and development of the dementia depend on the different mechanisms, it may be an advantageous to use the combination of drugs working 30 in different mechanism for the treatment of AD. The current approved treatment for AD includes the combination of acetylcholinesterase inhibitor, donepezil and
WO 2018/033848
PCT/IB2017/054939
NMDA receptor antagonist, memantine. However, there remains the need for the new drugs/combination to treat the patients with AD.
The compounds of the present invention are H3R inverse agonists with high affinity and very high selectivity over closely related receptor subtypes and 5 improves learning and memory in animals. The H3R inverse agonist compounds mentioned here are described in US9079888B2 which is incorporated by reference. The preparation of these compounds is given in the said patent.
As the treatment of AD is chronic in nature, there is a desperate unmet medical need for better and safer treatment options. A therapeutic strategy eagerly 10 sought for AD patients is to target an improvement with an adjunct to existing therapies that would bring additional relief for patients, lower the burden on the caregiver and allow the patient to enjoy a better quality of life without the need for institutional care and/or hospitalization.
The instant invention provides H3R inverse agonist compounds or the 15 pharmaceutically acceptable salt(s) thereof, which enhances the cognitive function of patients on treatment in combination with AChEIs and NMDA receptor antagonist. The present invention is based on the unusual finding that the combination of compounds with H3R inverse agonist activity, the compounds which act as AChEIs (for example donepezil) and the compounds which act as 20 NMDA receptor antagonists (for example memantine), demonstrate synergistic effect in their pharmacological activity. Memantine acts by blocking the glutamatergic neurotransmissions in the brain when the levels are excessively high. Histamine modulates the release of glutamate from corticostriatal nerve terminals. Hence it is not anticipated that the combination of a H3R inverse 25 agonist + donepezil + memantine would result in synergistic pro-cognitive effects.
However surprisingly, the combination of H3R inverse agonist + AChEIs + NMDA receptor antagonist (triple combination) showed synergistic effects in animal models and also increased the levels acetylcholine, the neurotransmitter which plays a vital role in cognitive improvement. Based on these results one can 30 infer that such combined administration and/or co-treatment of H3R inverse agonist + AChEIs + NMDA receptor antagonist, may result in beneficial effect to
WO 2018/033848
PCT/IB2017/054939 improve the therapeutic efficacy in humans. Further the H3R inverse agonist compounds or the pharmaceutically acceptable salt(s) thereof of the instant invention enhances the effect of the AChEIs and NMDA receptor antagonist in the treatment of cognitive disorders.
SUMMARY OF THE INVENTION
The objective of the present invention is to provide an improved combination therapy for the treatment of cognitive disorders, such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia, vascular 10 dementia, frontotemporal dementia, Down syndrome or Tourette’s syndrome.
In the first aspect, the present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist.
In yet another aspect, the present invention relates to a combination of histamine-3 inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist; wherein the histamine-3 receptor inverse agonist is selected from:
N - [4-(l-Cyclobutylpiperidin-4-yloxy)phenyl] -2-(morpholin-4yljacetamide;
N- [4-( 1 -Cycloprop ylpiperidin-4-yloxy)phenyl] -2-(morpholin-420 yljacetamide; and
N- [4-( 1 -Isopropylpiperidin-4-yloxy)phenyl] -2-(morpholin-4-yl)acetamide;
or a pharmaceutically acceptable salt thereof.
In another aspect, the present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA 25 receptor antagonist; wherein the histamine-3 receptor inverse agonist is N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.
In another aspect, the present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA 30 receptor antagonist; wherein the histamine-3 receptor inverse agonist is N-[4-(l4
WO 2018/033848
PCT/IB2017/054939
Cyclopropylpiperidin-4-yloxy)phenyl] -2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.
In another aspect, the present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA 5 receptor antagonist; wherein the histamine-3 receptor inverse agonist is N-[4-(lIsopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.
In another aspect, the present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA 10 receptor antagonist; wherein the acetylcholinesterase inhibitor is selected from donepezil, galantamine and rivastigmine or a pharmaceutically acceptable salt thereof.
In another aspect, the present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA 15 receptor antagonist; wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.
In yet another aspect the present invention relates to a combination of N[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, donepezil and memantine or a pharmaceutically acceptable salt thereof.
In yet another aspect the present invention relates to the combination of N[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, donepezil and memantine or a pharmaceutically acceptable salt thereof.
In yet another aspect the present invention relates to the combination of N[4-(l-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, donepezil 25 and memantine or a pharmaceutically acceptable salt thereof.
In yet another aspect, the present invention relates to the said combination for use in the treatment of cognitive disorders.
In yet another aspect, the present invention relates to the said combination for use in the treatment of cognitive disorders such as Alzheimer’s disease, 30 schizophrenia, Parkinson’s disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome or Tourette’s syndrome.
WO 2018/033848
PCT/IB2017/054939
In yet another aspect, the present invention relates to a method of treatment of cognitive disorders such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome or Tourette’s syndrome comprising administering to a 5 patient in need thereof a therapeutically effective amount of the said combination.
In yet another aspect, the present invention relates to histamine-3 receptor inverse agonist for use in the adjunct treatment of cognitive disorders such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome or Tourette’s 10 syndrome in patients on treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In yet another aspect, the present invention relates to the compound, N-[4(l-Cyclobutylpiperidin-4-yloxy)phenyl] -2-(morpholin-4-yl) acetamide or a pharmaceutically acceptable salt thereof for use in the adjunct treatment of 15 cognitive disorders such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome or Tourette’s syndrome in patients on treatment with donepezil and memantine.
In yet another aspect, the present invention relates to the compound, N-[420 (l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof for use in combination with or adjunct to an acetylcholinesterase inhibitor and NMDA receptor antagonist for the treatment of cognitive disorders such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down 25 syndrome or Tourette’s syndrome.
In another aspect, the present invention relates to a method for treatment of cognitive disorders comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]2-(morpholin-4-yl) acetamide or a pharmaceutically acceptable salt thereof in 30 combination with or as an adjunct to donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.
WO 2018/033848
PCT/IB2017/054939
In yet another aspect, the present invention relates to use of a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist for the treatment of cognitive disorders such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome or Tourette’s syndrome.
In yet another aspect, the present invention relates to use of a combination of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, donepezil and memantine or a pharmaceutically acceptable salt thereof for the treatment of cognitive disorders such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome or Tourette’s syndrome.
In another aspect, the present invention relates to pharmaceutical composition comprising the histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist and pharmaceutically acceptable excipients or combination thereof.
In another aspect, the present invention relates to pharmaceutical composition comprising N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2(morpholin-4-yl)acetamide, donepezil and memantine or a pharmaceutically acceptable salt thereof and the pharmaceutically acceptable excipients or combination thereof.
In another aspect, the present invention relates to pharmaceutical composition comprising the histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist or the pharmaceutically acceptable salt thereof along with the pharmaceutically acceptable excipients or combination thereof for use in the treatment of cognitive disorders such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome or Tourette’s syndrome.
WO 2018/033848
PCT/IB2017/054939
BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
Figure la depicts the results of the effect of a co-treatment of compound 1 with donepezil and memantine on cognition enhancing properties using object recognition task model.
Figure lb depicts the results of the effect of a co-treatment of compound 3 with donepezil and memantine on cognition enhancing properties using object recognition task model.
Figure 2 depicts the effect of compound 1 in combination with donepezil and memantine on extracellular levels of acetylcholine in medial prefrontal cortex of 10 male Wistar rats.
Figure 3 depicts the effect of compound 2 in combination with donepezil and memantine on extracellular levels of acetylcholine in medial prefrontal cortex of male Wistar rats.
Figure 4 depicts the effect of compound 3 in combination with donepezil and memantine on extracellular levels of acetylcholine in medial prefrontal cortex of male Wistar rats.
Figure 5 depicts the effect of compound 1 in combination with donepezil and memantine on evoked theta levels in dorsal hippocampus of anesthetized male Wistar rats.
DETAILED DESCRIPTION OF THE INVENTION
Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:
The term, “histamine-3 receptor inverse agonist” as used herein refers to a ligand or drug that binds with the constitutively active histamine-3 receptors, stabilize them and thus reduce the activity (negative intrinsic activity). It blocks or inhibits the function / binding of agonist at the H3 receptor and exert opposite pharmacological effect of a receptor agonist.
Examples of the histamine-3 receptor inverse agonist include,
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and
WO 2018/033848
PCT/IB2017/054939
N- [4-( 1 -Isopropylpiperidin-4-yloxy)phenyl] -2-(morpholin-4-yl)acetamide; or a pharmaceutically acceptable salt thereof.
Examples of pharmaceutically acceptable salt of the above identified compounds include but not limited to,
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride; N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4yl)acetamide tartrate; and
N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate.
The term, “acetylcholinesterase inhibitor” as used herein is a chemical or 10 drug that inhibits the acetylcholinesterase enzyme from breaking down acetylcholine, thereby increasing both the level and duration of action of the neurotransmitter acetylcholine. Examples of acetylcholinesterase inhibitor are donepezil, rivastigmine and galantamine. Preferably, the acetylcholinesterase inhibitor is donepezil and rivastigmine. More preferably the acetylcholinesterase 15 inhibitor is donepezil.
Donepezil is a drug approved for treatment of mild, moderate and severe dementia of Alzheimer’s disease. Donepezil is a reversible inhibitor of the enzyme acetylcholinesterase and sold under trade name Aricept® as hydrochloride salt.
Rivastigmine is a drug approved for treatment of mild, moderate and severe dementia of Alzheimer’s disease. Rivastigmine is a reversible cholinesterase inhibitor and sold under trade name Exelon® and Exelon Patch® as tartrate salt.
Galantamine is a drug approved for treatment of mild, moderate and 25 severe dementia of Alzheimer’s disease. Galantamine, a reversible, competitive acetylcholinesterase inhibitor and sold under trade name Razadyne® as hydrobromide salt.
The term, “NMDA receptor antagonist” as used herein refers to class of compounds which act on glutamatergic system by inhibiting the NMDA receptor.
Example of NMDA receptor antagonist is memantine. Memantine is a drug approved for treatment of moderate to severe dementia of the Alzheimer’s
WO 2018/033848
PCT/IB2017/054939 disease. Memantine is NMDA receptor antagonist and sold under trade name Namenda® and Namenda XR® as hydrochloride salt.
The combination of memantine and donepezil is approved for the treatment of moderate to severe dementia of the Alzheimer's disease and sold TM under trade name Namzaric as memantine hydrochloride salt and donepezil hydrochloride salt.
The phrase, therapeutically effective amount is defined as an amount of a compound of the present invention that (i) treats the particular disease, condition or disorder, (ii) eliminates one or more symptoms of the particular disease, condition or disorder and (iii) delays the onset of one or more symptoms of the particular disease, condition or disorder described herein.
The term, “pharmaceutically acceptable salt” as used herein refers to salts of the active compound and are prepared by reaction with the appropriate organic or inorganic acid or acid derivative, depending on the particular substituents found on the compounds described herein.
The term, “patient” as used herein refers to an animal. Preferably the term “patient” refers to mammal. The term mammal includes animals such as mice, rats, dogs, rabbits, pigs, monkeys, horses and human. More preferably the patient is human.
The term, “Alzheimer’s disease” as used herein refers to a dementia that causes problems with memory, thinking and behavior. The Alzheimer’s disease can be mild to moderate to severe Alzheimer’s disease.
The compound 1 as used herein is N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride which has the chemical structure, . 2 HCl
WO 2018/033848
PCT/IB2017/054939
The compound 2 as used herein is N-[4-(l-Cyclopropylpipendin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate which has the chemical structure,
The compound 3 as used herein is N-[4-(l-Isopropylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate which has the chemical structure,
The term, treatment' or 'treating as used herein refers to any treatment of a disease in a mammal, including: (a) slowing or arresting the development of clinical symptoms; and/or (b) causing the regression of clinical symptoms.
The term, compound for use as used herein embrace any one or more of the following: (1) use of a compound, (2) method of use of a compound, (3) use in the treatment of, (4) the use for the manufacture of pharmaceutical composition / medicament for treatment / treating or (5) method of treatment / treating / preventing / reducing / inhibiting comprising administering an effective amount of the active compound to a subject in need thereof.
The term, “cognitive disorder” as used herein refers to a group of mental health disorders that principally affect learning, memory, perception and problem solving and includes amnesia, dementia and delirium. Cognitive disorders can result due to disease, disorder, ailment or toxicity. Example of cognitive disorders includes but not limited to, Alzheimer’s disease, schizophrenia, Parkinson’s disease, lewy body dementia (LBD), vascular dementia, frontotemporal dementia (FTD), Down syndrome or Tourette’s syndrome. Preferably, the cognitive disorder is Alzheimer’s disease.
The term, “adjunct” or “adjunctive treatment” as used herein refers to an additional treatment to a patient who has already received at least one other
WO 2018/033848
PCT/IB2017/054939 therapy for cognitive disorders. A drug used as adjunctive therapy is administered to a patient to make that primary treatment works better.
Embodiments
The present invention encompasses all the combinations described herein without limitation, however, preferred aspects and elements of the invention are discussed herein in the form of the following embodiments.
In one embodiment, the present invention relates to the combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist; wherein the histamine-3 receptor inverse agonist is N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.
In another embodiment, the present invention relates to the combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist; wherein the histamine-3 receptor inverse agonist is N-[4-(lCyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate.
In another embodiment, the present invention relates to the combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist; wherein the histamine-3 receptor inverse agonist is N-[4-(lIsopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate.
In another embodiment, the present invention relates to the combination of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, rivastigmine and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to the combination of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, galantamine and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to the combination of N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, rivastigmine and memantine or a pharmaceutically acceptable salt thereof.
WO 2018/033848
PCT/IB2017/054939
In another embodiment, the present invention relates to the combination of N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, galantamine and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to the combination of 5 N- [4-( 1 -Isopropylpiperidin-4-yloxy)phenyl] -2-(morpholin-4-yl)acetamide, rivastigmine and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to the combination of N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide, galantamine and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to the combination of
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, donepezil hydrochloride and memantine hydrochloride.
In another embodiment, the present invention relates to the combination of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, rivastigmine tartrate and memantine hydrochloride.
In another embodiment, the present invention relates to the combination of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, galantamine hydrobromide and memantine hydrochloride.
In another embodiment, the present invention relates to the combination of 20 N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate, donepezil hydrochloride and memantine hydrochloride.
In another embodiment, the present invention relates to the combination of N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate, rivastigmine tartrate and memantine hydrochloride.
In another embodiment, the present invention relates to the combination of
N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate, galantamine hydrobromide and memantine hydrochloride.
In another embodiment, the present invention relates to the combination of N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate, 30 donepezil hydrochloride and memantine hydrochloride.
WO 2018/033848
PCT/IB2017/054939
In another embodiment, the present invention relates to the combination of N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate, rivastigmine tartrate and memantine hydrochloride.
In another embodiment, the present invention relates to the combination of
N-[4-( 1 -Isopropylpiperidin-4-yloxy)phenyl] -2-(morpholin-4-yl)acetamide tartrate, galantamine hydrobromide and memantine hydrochloride.
In another embodiment, the present invention provides the combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist which is more effective than the combination of histamine-3 10 receptor inverse agonist and acetylcholinesterase inhibitor, acetylcholinesterase inhibitor and NMDA receptor antagonist or histamine-3 receptor inverse agonist and NMDA receptor antagonist.
In another embodiment, the present invention provides the combination of the histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and 15 NMDA receptor antagonist which is more effective than the histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist alone.
In another embodiment, the present invention provides the combination of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, donepezil hydrochloride and memantine hydrochloride which is more effective than the combination of N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride and donepezil hydrochloride, donepezil hydrochloride and memantine hydrochloride or N-[4-(1Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride and memantine hydrochloride.
In another embodiment, the present invention provides the combination of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, donepezil hydrochloride and memantine hydrochloride which is more effective than N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-430 yl)acetamide dihydrochloride, donepezil hydrochloride and memantine hydrochloride alone.
WO 2018/033848
PCT/IB2017/054939
In another embodiment the pharmaceutically acceptable salt of histamine3 receptor inverse agonist includes but not limited to, dihydrochloride salt, oxalate salt, succinate, tartrate salt and the like. Preferably, the pharmaceutically acceptable salt is dihydrochloride salt and tartrate salts. More preferably, the pharmaceutically acceptable salt is dihydrochloride salt.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of the said combination.
In another embodiment, the present invention relates to a method of 10 treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof, acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Cyclopropylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof, acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of 20 treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof, acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of 25 treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof
WO 2018/033848
PCT/IB2017/054939 a therapeutically effective amount of N-[4-(l-Cyclopropylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Cyclopropylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]2-(morpholin-4-yl)acetamide tartrate in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride in combination with donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.
WO 2018/033848
PCT/IB2017/054939
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride in combination with 5 donepezil hydrochloride and memantine hydrochloride.
In another embodiment, the present invention relates to the combination of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, acetylcholinesterase inhibitor and NMDA receptor antagonist for use in the treatment of Alzheimer’s disease.
In yet another aspect, the present invention relates to N-[4-(1Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof for use in the adjunct treatment of Alzheimer’s disease in a patient on treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In yet another aspect, the present invention relates to N- [4-(1Cyclopropylpiperidin-4-yloxy)phenyl] -2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof for use in the adjunct treatment of Alzheimer’s disease in a patient on treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In yet another aspect, the present invention relates to N- [4-(1Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof for use in the adjunct treatment of Alzheimer’s disease in a patient on treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride for use in the adjunct treatment of Alzheimer’s disease in a patient on treatment with donepezil and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to N-[4-(lCyclopropylpiperidin-4-yloxy)phenyl] -2-(morpholin-4-yl)acetamide tartrate for
WO 2018/033848
PCT/IB2017/054939 use in the adjunct treatment of Alzheimer’s disease in a patient on treatment with donepezil and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to N-[4-(l-Isopropyl piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate for use in the adjunct treatment of Alzheimer’s disease in a patient on treatment with donepezil and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to use of the combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist in the manufacture of a medicament for 10 treatment of Alzheimer’s disease.
In another embodiment, the present invention relates to use of histamine-3 receptor inverse agonist in the manufacture of a medicament for treatment of Alzheimer’s disease in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to use of histamine-3 receptor inverse agonist in the manufacture of a medicament for treatment of Alzheimer’s disease as adjunct to acetylcholinesterase inhibitor and NMDA receptor antagonist.
In another embodiment, the present invention relates to use of the N-[4-(l20 Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer’s disease in combination with donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to use of the N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride in the manufacture of a medicament for treatment of Alzheimer’s disease in combination with donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention relates to use of N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide
WO 2018/033848
PCT/IB2017/054939 dihydrochloride in the manufacture of a medicament for treatment of Alzheimer’s disease in combination with donepezil hydrochloride and memantine hydrochloride.
In another embodiment, the present invention relates to histamine-3 receptor inverse agonist for use in the treatment of Alzheimer’s disease in combination with Namzaric™.
In another embodiment, the present invention relates to a method of treating Alzheimer’s disease comprising administering to a patient in need thereof a therapeutically effective amount of histamine-3 receptor inverse agonist in
TM combination with Namzaric .
In another embodiment, the present invention relates to the combination for treatment of Alzheimer’s disease, wherein Alzheimer’s disease is mild Alzheimer’s disease.
In another embodiment, the present invention relates to the combination for treatment of Alzheimer’s disease, wherein the Alzheimer’s disease is moderate Alzheimer’s disease.
In another embodiment, the present invention relates to the combination for treatment of Alzheimer’s disease, wherein the Alzheimer’s disease is severe Alzheimer’s disease.
In another embodiment, the present invention relates to the combination wherein the active ingredients can be administered to a patient concurrently or separately.
In yet another aspect, the active ingredients of the combination of the present invention are normally administered by formulating the active ingredients 25 into a pharmaceutical composition in accordance with standard pharmaceutical practice.
In yet another aspect, the active ingredients of the combination of the present invention may be administered by oral, nasal, local, dermal or parenteral routes.
In yet another aspect, the active ingredients of the combination of the present invention can be administered by the same or different route of
WO 2018/033848
PCT/IB2017/054939 administration. For instance, the histamine-3 receptor inverse agonist of the instant invention can be administered orally, the acetylcholinesterase inhibitor can be administered transdermally and the NMDA receptor antagonist can be administered locally.
The pharmaceutical compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable excipients. The pharmaceutically acceptable excipients are diluents, disintegrants, binders, lubricants, glidants, polymers, coating agents, solvents, cosolvents, preservatives, wetting agents, thickening agents, antifoaming agents, 10 sweetening agents, flavouring agents, antioxidants, colorants, solubilizers, plasticizer, dispersing agents and the like. Excipients are selected from microcrystalline cellulose, mannitol, lactose, pregelatinized starch, sodium starch glycolate, corn starch or derivatives thereof, povidone, crospovidone, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, talc, colloidal silicone 15 dioxide, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid or hydrogenated vegetable oil, gum arabica, magnesia, glucose, fats, waxes, natural or hardened oils, water, physiological sodium chloride solution or alcohols, for example, ethanol, propanol or glycerol, sugar solutions, such as glucose solutions or mannitol solutions and the like or a mixture 20 of the various excipients.
In yet another aspect, the active compounds of the invention may be formulated in the form of pills, tablets, coated tablets, capsules, powder, granules, pellets, patches, implants, films, liquids, semi-solids, gels, aerosols, emulsions, elixirs and the like. Such pharmaceutical compositions and processes for 25 preparing same are well known in the art.
In yet another aspect, the pharmaceutical composition of the instant invention contains 1 to 90 %, 5 to 75 % and 10 to 60 % by weight of the compounds of the instant invention or pharmaceutically acceptable salt thereof. The amount of the active compounds or its pharmaceutically acceptable salt in the 30 pharmaceutical composition(s) can range from about 0.1 mg to about 100 mg or
WO 2018/033848
PCT/IB2017/054939 from about 0.1 mg to about 60 mg or from about 0.1 mg to about 30 mg or in any range falling within the broader range of 0.1 mg to 100 mg.
In yet another aspect, the pharmaceutical composition of the combination of the instant invention can be conventional formulations such as immediate 5 release formulations, modified release formulations such as sustained release formulations, delayed release formulations and extended release formulations or new delivery systems such as oral disintegrating formulations and transdermal patches.
The dose of the active compounds can vary depending on factors such as 10 age and weight of patient, nature, route of administration and severity of the disease to be treated and such other factors. Therefore, any reference regarding pharmacologically effective amount of the compounds 1, 2 and 3 refers to the aforementioned factors.
In yet another aspect, the histamine-3 receptor inverse agonist can be co15 administered with acetylcholinesterase inhibitor and NMD A receptor antagonist at a daily dose of 0.1 mg to 100 mg; such as 0.1, 0.5, 0.75, 1, 1.5, 3, 5, 6, 10, 20, 25, 30, 50, 75 and 100 mg, preferably at a daily dose of 0.1, 3, 5, 6, 10, 20, 25, 30 or 50 mg and most preferably at a daily dose of 0.5, 3, 5, 10 or 20 mg.
In yet another aspect, the acetylcholinesterase inhibitor can be co20 administered with histamine-3 receptor inverse agonist and NMDA receptor antagonist at a daily dose of 1 mg to 30 mg; such as 1, 1.5, 2, 3, 4, 4.5, 5, 6, 8, 9.5,10, 12, 13, 13.3, 15, 16, 23, 24, 25 or 30 mg, preferably at a daily dose of 1, 1.5, 2, 3, 4, 4.5, 5, 6, 8, 9.5, 10, 12, 13, 13.3, 16, 23, 24, or 25 mg and most preferably at a daily dose of 1.5, 3, 4, 4.5, 5, 6, 8, 9.5, 10, 12, 13.3, 16, 23 or 24 25 mg.
In yet another aspect, the NMDA receptor antagonist, memantine can be co-administered with histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor at a daily dose of 1 mg to 40 mg; such as 5, 7, 10, 14, 20, 28 or 40 mg, preferably at a daily dose of 5, 7, 10, 14, 20 or 28 mg and 30 most preferably at a daily dose of 5, 10, 14, 20 or 28 mg.
WO 2018/033848
PCT/IB2017/054939
In yet another aspect, the acetylcholinesterase inhibitor, donepezil can be co-administered with histamine-3 receptor inverse agonist and NMDA receptor antagonist at a daily dose of 2 mg to 30 mg; such as 2, 5, 10, 15, 23, 25 or 30 mg, preferably at a daily dose of 2, 5, 10, 23 or 25 mg and most preferably at a daily 5 dose of 5, 10 or 23 mg.
In yet another aspect, the acetylcholinesterase inhibitor, rivastigmine can be co-administered with histamine-3 receptor inverse agonist and NMDA receptor antagonist at a daily dose of 0.5 mg to 15 mg; such as 1, 1.5, 3, 4.5, 5, 6, 9.5, 10 or 13.3 mg, preferably at a daily dose of 1, 1.5, 3, 4.5, 5, 6, 9.5 or 13.3 mg and most 10 preferably at a daily dose of 1.5, 3, 4.5, 6, 9.5 and 13.3 mg.
In yet another aspect, the acetylcholinesterase inhibitor, galantamine can be co-administered with histamine-3 receptor inverse agonist and NMDA receptor antagonist at a daily dose of 1 mg to 30 mg; such as 1, 2, 4, 6, 8, 12, 16, 24 and 30 mg, preferably at a daily dose of 2, 4, 6, 8, 12, 16 and 24 mg and most preferably 15 at a daily dose of 4, 8, 12, 16 and 24 mg.
In yet another aspect, the treatment comprises administering to the patient 0.1 mg to 100 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin4-yl)acetamide or a pharmaceutically acceptable salt thereof, per day.
In yet another aspect, the treatment comprises administering to the patient 20 0.1 mg to 60 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4yl)acetamide or a pharmaceutically acceptable salt thereof, per day.
In yet another aspect, the treatment comprises administering to the patient 0.1 mg to 30 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4yl)acetamide or a pharmaceutically acceptable salt thereof, per day.
In yet another aspect, the treatment comprises administering to the patient mg to 25 mg of donepezil or a pharmaceutically acceptable salt thereof, per day.
In yet another aspect, the treatment comprises administering to the patient 5 mg to 25 mg of donepezil or a pharmaceutically acceptable salt thereof, per day.
In yet another aspect, the treatment comprises administering to the patient,
5, 10 or 23 mg of donepezil or a pharmaceutically acceptable salt thereof, per day.
WO 2018/033848
PCT/IB2017/054939
In yet another aspect, the treatment comprises administering to the patient 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof, per day.
In yet another aspect, the treatment comprises administering to the patient 5 mg to 30 mg of memantine or a pharmaceutically acceptable salt thereof, per day.
In yet another aspect, the treatment comprises administering to the patient 5, 10, 14, 20 or 28 mg of memantine or a pharmaceutically acceptable salt thereof, per day.
In yet another aspect, the treatment comprises administering the active compounds to the patient one to three times per day, one to three times per week or one to three times per month. Preferably, the treatment comprises administering the compound to a patient once a day, twice a day, or thrice a day. More preferably, the treatment comprises administering the compound to a patient once a day.
Examples
The examples given below are provided by the way of illustration only and therefore should not be construed to limit the scope of the invention.
Abbreviations:
| ANOVA | Analysis of variance |
| AP | Anterior Posterior |
| aCSF | Artificial Cerebrospinal fluid |
| CaCl2. 2H2O | Calcium chloride dihydrate |
| DV | Dorsal Ventral |
| DTT | Dithiothreitol |
| EC50 | Half maximal effective concentration |
| EDTA | Ethylenediaminetetraacetic acid |
| EEG | Electroencephalogram |
| GDP | Guanosine diphosphate |
| GPCR | G-Protein Coupled Receptor 23 |
WO 2018/033848
PCT/IB2017/054939
| HC1 | Hydrochloric acid |
| h | Hour (s) |
| HEPES | 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid |
| i.p. | Intraperitoneal |
| i.v. | Intravenous |
| KC1 | Potassium chloride |
| Kb | Binding constant |
| K, | Inhibitory constant |
| LC-MS/MS | Liquid chromatography-Mass spectrometry/ Mass spectrometry |
| mg | Milligram |
| MgCl2 | Magnesium chloride |
| min | Minute (s) |
| ML | Medial Lateral |
| mM | Millimolar |
| nmol/L | Nanomoles per litre |
| NaCl | Sodium chloride |
| NaH2PO4.2H2O | Sodium dihydrogen phosphate dihydrate |
| Na2HPO4.7H2O | Sodium monohydrogen phosphate heptahydrate |
| NPO | Nucleus Pontis Oralis |
| nM | Nanomolar |
| p.o. | Per oral |
| s.c. | Subcutaneous |
| S.E.M. | Standard error of the mean |
| μΜ | Micromolar |
| Θ | Theta |
Example 1: Determination of Kj value at human and rat histamine-3 receptor
Test compounds were evaluated according to the following procedures to determine the Ki value at human and rat histamine-3 receptor.
Materials and Methods:
WO 2018/033848
PCT/IB2017/054939
Receptor source: Rat brain frontal cortex or recombinant human cDNA expressed in CHO cells
Radioligand: [3H] R-a-methylhistamine Final ligand concentration: [3.0 nM] Non-specific determinant: R-a-methylhistamine (100 μΜ) Reference compound: R-a-methylhistamine Positive control: R-a-methylhistamine
Incubation conditions:
Increasing concentrations of test compounds or standard were incubated with membrane receptors and radioligand in 5 mM MgCh and 50 mM TRIS-HC1 (pH 7.4) for 60 minutes at room temperature. The reaction was terminated by rapid vacuum filtration onto the glass fiber filters. Radioactivity trapped onto the filters was determined and compared to the control values in order to ascertain any interactions of the test compound(s) with either cloned human or rat receptor binding site.
Results:
| S.No | Example | Human histamine-3 receptor Ki (nM) | Rat histamine-3 receptor Ki (nM) |
| 1 | Compound 1 | 8.7 | 9.8 |
| 2 | Compound 2 | 19.9 | ND |
| 3 | Compound 3 | 8.3 | ND |
ND-Not done
Reference:
Br J Pharmacol., 2008, 154(6): 1166-1181.
Example 2: Determination of IC50 values at histamine-3 receptor
Test compounds were evaluated according to the following procedures to determine the IC50 values.
Materials and Methods:
Receptor source: Human recombinant (CHO-K1 cells)
Radioligand: [35S]-GTPyS
Final ligand concentration: [0.3 nM]
WO 2018/033848
PCT/IB2017/054939
Reference compound:
Positive control:
Thioperamide
Thioperamide
Incubation conditions:
Increasing concentrations of test compounds and/or vehicle is preincubated with the membranes (0.09 mg/mL) and 10 μΜ GDP in modified HEPES pH 7.4 buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, 1 mM EDTA) for 20 minutes and SPA beads are then added for another 60 minutes at 30°C. The reaction is initiated by 0.3 nM [35S]GTPyS for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTPyS binding by 50 percent or more (>50 %) relative to the 3 μΜ R(-)-amethylhistamine response indicates possible histamine-3 receptor agonist activity. Test compound induced inhibition of 0.03 μΜ R(-)-a-methylhistamine-induced increase of [ S]GTPyS binding response by 50 percent or more (>50 %) indicates receptor antagonist activity. These studies were conducted and the data were analyzed at Eurofins Panlabs Taiwan Ltd, Taiwan using standard radioligand binding techniques as described above.
Results:
Compound 1 exhibits inverse agonist like properties in GTPyS assay on human recombinant histamine-3 receptor with IC50 value of 20 nM.
Reference:
J. Neurochem., 1998, 71(2): 808-816.
Example 3: Object Recognition Task Model
The cognition enhancing properties of compounds of this invention were estimated by using this model.
Male Wistar rats (8-10 weeks old) were used as experimental animals. Four animals were housed in each cage. Animals were kept on 20 % food deprivation from a day prior to experimentation. Water was provided ad libitum throughout the experiment. Animals were maintained on a 12 hours light/dark cycle in temperature and humidity controlled room. The experiment was carried
WO 2018/033848
PCT/IB2017/054939 out in an open field made up of acrylic. Rats were habituated to individual arenas (open field) in the absence of any objects on day 1.
Rats received vehicle, donepezil and memantine or test compound, donepezil and memantine on the day of habituation, before familiar (Ti) and 5 choice (T2) trials. During the familiarization phase (Ti), the rats were placed individually in the arena for 3 minutes, in which two identical objects (ai and a2) were positioned 10 cm from the wall. 24 hours after Ti, trial for long-term memory test was assessed. The same rats were placed in the same arena as they were placed in Ti trial. During the choice phase (T2) rats were allowed to explore 10 the arena for 3 minutes in presence of a copy of familiar object (a3) and one novel object (b). During the Ti and T2 trial, explorations of each object (defined as sniffing, licking, chewing or having moving vibrissae whilst directing the nose towards the object at a distance of less than 1 cm) were recorded using stopwatch.
Ti is the total time spent exploring the familiar objects (ai + a2).
T2 is the total time spent exploring the familiar object and novel object (a3 +b).
Discriminative index is ratio of time spent exploring the novel object divided by sum of time spent exploring the novel object and familiar object in choice trial (T2).
The object recognition test was performed as described in Behavioural
Brain Research, 1988, 31, 47-59.
Results:
Vehicle treated animals spent almost equal time exploring the novel and the familiar objects. The groups treated with combination of test compound, 25 donepezil and memantine spent significantly more time exploring the novel object. No significant increase in discriminative index was observed in the group treated with donepezil and memantine when compared to the vehicle treatment. However the group co-treated with test compounds, donepezil and memantine showed significant improvement in the memory end point (discriminative index). 30 This procognitive effect suggests a potentiating effect of test compounds over the
WO 2018/033848
PCT/IB2017/054939 procognitive effect of donepezil and memantine. The results of this study are provided in figure la and lb.
Example 4: Evaluation of acetylcholine modulation in medial prefrontal cortex of male Wistar rats
Neurotransmitter modulating effects of triple combination were evaluated by this model.
Male Wistar rats (240-300 g body weight) were stereotaxically implanted with a microdialysis guide cannula in medial prefrontal cortex (mPFC; AP: +3.2 mm, ML: -0.5 mm, DV: -3.0 mm) under isoflurane anesthesia. Co-ordinates were taken according to atlas for the rat brain (Paxinos and Watson, 2004) with reference points taken from bregma and vertical from the skull. The rats were allowed to recover individually for four days in a round bottom Plexiglas bowl with free access to feed and water.
After surgical recovery of 4 days, male Wistar rats were connected to dual quartz lined two-channel liquid swivel (Instech, UK) on a counter balance lever arm, which allowed unrestricted movements of the animal. Sixteen hours before start of the study, a pre-equilibrated microdialysis probe (2 mm dialysis membrane) was inserted into mPFC through the guide cannula. On the day of study, probe was perfused with artificial cerebrospinal fluid (aCSF; NaCl 147 mM, KC1 2.7 mM, MgCl2 1 mM, CaCl2. 2H2O 1.2 mM, pH 7.4) at a flow rate of
1.5 pL/min and a stabilization period of 2 hours was maintained. Five basal samples were collected at 20 min intervals prior to the treatment of test compounds (3 or 10 mg/kg, p.o.} or vehicle. Donepezil (1 mg/kg, s.c.} and memantine (1 mg/kg, s.c.) were administered 30 min after administration of test compounds. Dialysate samples were collected for an additional period of 4 h post treatment of test compounds. Dialysates were stored below -50°C prior to analysis.
Quantitation of acetylcholine:
Acetylcholine concentrations in dialysates were quantified using LCMS/MS based method.
WO 2018/033848
PCT/IB2017/054939
Statistical analysis:
All microdialysis data for acetylcholine was plotted as percent change from mean dialysate basal concentrations with 100 % defined as the average of five pre-dose values. The percent change in acetylcholine levels were compared 5 with donepezil and memantine combination using two-way analysis of variance (time and treatment), followed by Bonferroni’s posttest. Area under the curve (AUC) values for percent change in acetylcholine levels was calculated and the statistical significance between the mean AUC values was compared against donepezil and memantine treatment using unpaired “f ’ test. Statistical significance 10 was considered at a p value less than 0.05. Incorrect probe placement was considered as criteria to reject the data from animal.
Reference:
1. Paxinos G. and Watson C. (2004) Rat brain in stereotaxic coordinates. Academic Press, New York.
Results:
Compound 1
Treatment with donepezil and memantine produced increase in acetylcholine levels to the maximum of 1726 ± 297 % of basal levels. The increase in acetylcholine after combination of compound 1, donepezil and 20 memantine was significantly higher compared to donepezil and memantine combination. Mean maximum increase in acetylcholine was observed to be 2968 ±585 of pre-dose levels after triple combination (Figure 2(a)).
Mean area under the curve values (AUC) calculated after the treatment of compound 1, donepezil and memantine were significantly higher compared to 25 donepezil and memantine combination (Figure 2(b)).
Compound 2
Treatment with donepezil and memantine produced increase in acetylcholine levels to the maximum of 1365 ± 249 % of basal levels. The increase in acetylcholine after combination of compound 2, donepezil and 30 memantine was significantly higher compared to donepezil and memantine
WO 2018/033848
PCT/IB2017/054939 combination. Mean maximum increase in acetylcholine was observed to be 2696 ± 504 % of pre-dose levels after triple combination (Figure 3(a)).
Mean area under the curve values (AUC) calculated after treatment of compound 2, donepezil and memantine were significantly higher compared to 5 donepezil and memantine combination (Figure 3(b)).
Compound 3
Treatment with donepezil and memantine produced increase in acetylcholine levels to the maximum of 1375 ± 461 % of basal levels. The increase in acetylcholine after combination of compound 3, donepezil and 10 memantine was significantly higher compared to donepezil and memantine combination. Mean maximum increase in acetylcholine was observed to be 2674 + 271 of pre-dose levels after triple combination (Figure 4(a)).
Mean area under the curve values (AUC) calculated after treatment of compound 3, donepezil and memantine were significantly higher compared to 15 donepezil and memantine combination (Figure 4(b)).
Example 5: Evaluation of theta modulation in dorsal hippocampus of anesthetized male Wistar rats
Effect of triple combination on brain activity as a pharmacodynamic 20 endpoint is evaluated using this model.
Male Wistar rats (240-320 g) were anesthetized by intraperitoneal administration of urethane (1.2 to 1.5 g/kg) for implantation of a catheter in the left femoral vein. The animal was placed in a stereotaxic frame for implanting an electrode (stainless steel wire, Plastics One) into the dorsal hippocampus (AP: 25 3.8 mm; ME: +2.2 mm; DV: -2.5 mm; Paxinos and Watson, 2004). Bipolar stimulating electrode (untwisted stainless steel wires, separated by 0.75-1.0 mm at their tips, Plastics One) was implanted in the Nucleus Pontis Oralis (NPO; AP: 7.8 mm; ME: 1.8 mm; DV: -6.0 mm; Paxinos and Watson, 2004). Additionally one electrode was implanted into the cerebellum which served as a reference.
Hippocampal Θ rhythm was evoked via a 6-s electrical stimulation train (20-160 μΑ, 0.3-ms pulse duration, 250 Hz) delivered to the NPO at a rate of 0.01 trains/s
2017311666 22 Feb 2019
In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word “comprise” or variations such as “comprises” or “comprising” is used in an inclusive sense, i.e. to specify the presence of the stated 5 features but not to preclude the presence or addition of further features in various embodiments of the invention.
It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any 10 other country.
Claims (21)
- We claim:1. A pharmaceutical composition comprising histamine-3 receptor inverse agonists, acetylcholinesterase inhibitor and NMDA receptor antagonist and optionally one or more pharmaceutically acceptable excipients; wherein the histamine-3 receptor inverse agonist is selected from N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; or a pharmaceutically acceptable salt thereof; the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof; and the NMDA receptor antagonist is selected from memantine or a pharmaceutically acceptable salts thereof.
- 2. The pharmaceutical composition as claimed in claim 1, wherein the histamine-3 receptor inverse agonist is present in an amount of 0.1 mg to 100 mg, 0.1 mg to 60 mg, 0.1 mg to 30 mg, the acetylcholinesterase inhibitor is present in an amount of 1 mg to 30 mg and/or the NMDA receptor antagonist is present in an amount of 1 mg to 40 mg.
- 3. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein the pharmaceutically acceptable salt of the histamine-3 receptor inverse agonist is selected from the group consisting of; N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride;N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate; and11512369_1 (GHMatters) P110553.AU2017311666 31 Jul 2019N-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate or another pharmaceutically acceptable salt thereof.
- 4. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein the acetylcholinesterase inhibitor is donepezil or donepezil hydrochloride or another pharmaceutically acceptable salt thereof and NMDA receptor antagonist is memantine or memantine hydrochloride or another pharmaceutically acceptable salt thereof.
- 5. A pharmaceutical composition comprising N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, the acetylcholinesterase inhibitor is donepezil hydrochloride and the NMDA receptor antagonist is memantine hydrochloride.
- 6. The pharmaceutical composition as claimed in any one of claims 1 to 5, wherein the composition is in a form suitable for oral, nasal, local, dermal or parenteral administration.
- 7. Use of the pharmaceutical composition as claimed in any one of claims 1 to 6, in the manufacture of a medicament for treating a cognitive disorder.
- 8. A method of treatment of cognitive disorders comprising administering to a patient in need thereof, a therapeutically effective amount of the pharmaceutical composition as claimed in any one of claims 1 to 10.
- 9. The use as claimed in claim 7, or the method as claimed in claim 8, wherein the cognitive disorder is selected from Alzheimer’s disease, schizophrenia, Parkinson’s disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette’s syndrome.11512369_1 (GHMatters) P110553.AU2017311666 31 Jul 2019
- 10. The use as claimed in claim 7 or claim 9, wherein the pharmaceutical composition comprises of 0.1 mg to 100 mg, 0.1 mg to 60 mg, 0.1 mg to 30 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt, 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof and 1 mg to 40 mg memantine or a pharmaceutically acceptable salt thereof.
- 11. The method as claimed in claim 8 or claim 9, wherein the pharmaceutical composition comprises 0.1 mg to 100 mg, 0.1 mg to 60 mg, 0.1 mg to 30 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt, 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof and/or 1 mg to 40 mg memantine or a pharmaceutically acceptable salt thereof.
- 12. Use of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4yl)acetamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Alzheimer’s disease in a patient on stable treatment with an acetylcholinesterase inhibitor and a NMDA receptor antagonist, or as an adjunctive treatment to acetylcholinesterase inhibitor and NMDA receptor antagonist.
- 13. A method of treating Alzheimer’s disease in a patient on stable treatment with an acetylcholinesterase inhibitor and a NMDA receptor antagonist or as an adjunctive treatment to NMDA receptor antagonist comprising administering to the patient a therapeutically effective amount of N-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.
- 14. The use as claimed in claim 12, or the method as claimed in claim 13, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof and11512369_1 (GHMatters) P110553.AU2017311666 31 Jul 2019NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.
- 15. The use as claimed in claim 12 or claim 14, or the method as claimed in claim 13 or claim 14, wherein the pharmaceutically acceptable salt of N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.
- 16. The use as claimed in any one of claims 12, 14 or 15, wherein the medicament comprises 0.1 mg to 100 mg, 0.1 mg to 60 mg, 0.1 mg to 30 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt and is co-administered with 1 to 30 mg of donepezil or a pharmaceutically acceptable salt thereof and 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof.
- 17. The method as claimed in claim 13 to 15, wherein the 0.1 mg to 100 mg, 0.1 mg to 60 mg, 0.1 mg to 30 mg ofN-[4-(l-Cyclobutylpiperidin-4yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt is co-administered with 1 to 30 mg of donepezil or a pharmaceutically acceptable salt thereof and 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof.
- 18. The use as claimed in any one of claims 12, 14 to 16, or the method as claimed in any one of claims 13 to 15 and 17, wherein the of N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt, acetylcholinesterase inhibitor and/or NMDA receptor antagonist is in a form suitable for oral, nasal, local, dermal or parenteral administration.11512369_1 (GHMatters) P110553.AU2017311666 31 Jul 2019
- 19. The use as claimed in any one of claims 12, 14 to 16, or the method as claimed in any one of claims 13 to 15 and 17, wherein the N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salts thereof is administered one to three times per day, one to three times per week, or one to three times per month.
- 20. Use of a histamine-3 receptor inverse agonists selected from N-[4-(lCyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; N-[4-(l-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; andN-[4-(l-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; or a pharmaceutically acceptable salt thereof, in combination with an acetylcholinesterase inhibitor is selected from donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof and a NMDA receptor antagonist selected from memantine or a pharmaceutically acceptable salt thereof, for the treatment of cognitive disorders in a patient.
- 21. The use as claimed as in claim 20, wherein the cognitive disorder is selected from Alzheimer’s disease, schizophrenia, Parkinson’s disease, Lewy body dementia, vascular dementia and frontotemporal dementia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028165 | 2016-08-18 | ||
| IN201641028165 | 2016-08-18 | ||
| PCT/IB2017/054939 WO2018033848A1 (en) | 2016-08-18 | 2017-08-14 | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017311666A1 AU2017311666A1 (en) | 2019-03-14 |
| AU2017311666B2 true AU2017311666B2 (en) | 2019-08-22 |
Family
ID=59829422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017311666A Ceased AU2017311666B2 (en) | 2016-08-18 | 2017-08-14 | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and NMDA receptor antagonist |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20190336509A1 (en) |
| EP (1) | EP3500306B1 (en) |
| JP (1) | JP6734469B2 (en) |
| KR (1) | KR102040639B1 (en) |
| CN (1) | CN109562180B (en) |
| AU (1) | AU2017311666B2 (en) |
| BR (1) | BR112019002637A2 (en) |
| CA (1) | CA3033050C (en) |
| CY (1) | CY1123522T1 (en) |
| DK (1) | DK3500306T3 (en) |
| EA (1) | EA036480B1 (en) |
| ES (1) | ES2818898T3 (en) |
| HR (1) | HRP20201511T1 (en) |
| HU (1) | HUE051474T2 (en) |
| IL (1) | IL264405B (en) |
| LT (1) | LT3500306T (en) |
| MA (1) | MA45988B1 (en) |
| MD (1) | MD3500306T2 (en) |
| MX (1) | MX2019001698A (en) |
| PL (1) | PL3500306T3 (en) |
| PT (1) | PT3500306T (en) |
| RS (1) | RS60832B1 (en) |
| SG (1) | SG11201900680PA (en) |
| SI (1) | SI3500306T1 (en) |
| WO (1) | WO2018033848A1 (en) |
| ZA (1) | ZA201900436B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020024264A2 (en) * | 2018-05-31 | 2021-02-23 | Suven Life Sciences Limited | inverted histamine-3 receptor agonist, use of an inverted histamine-3 receptor agonist for the manufacture of a drug and pharmaceutical composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140135304A1 (en) * | 2011-02-23 | 2014-05-15 | Suven Life Sciences Limited | Novel compounds as histamine h3 receptor ligands |
| WO2014136075A1 (en) * | 2013-03-06 | 2014-09-12 | Richter Gedeon Nyrt. | H3 antagonists containing phenoxypiperidine core structure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2974729B1 (en) * | 2011-05-02 | 2013-04-19 | Servier Lab | NOVEL ASSOCIATION BETWEEN 4- {3- [CIS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE AND AN ACETYLCHOLINESTERASE INHIBITOR AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
-
2017
- 2017-08-14 MX MX2019001698A patent/MX2019001698A/en active IP Right Grant
- 2017-08-14 MD MDE20190713T patent/MD3500306T2/en unknown
- 2017-08-14 CN CN201780048908.1A patent/CN109562180B/en active Active
- 2017-08-14 WO PCT/IB2017/054939 patent/WO2018033848A1/en unknown
- 2017-08-14 KR KR1020197007052A patent/KR102040639B1/en active IP Right Grant
- 2017-08-14 ES ES17764658T patent/ES2818898T3/en active Active
- 2017-08-14 SI SI201730420T patent/SI3500306T1/en unknown
- 2017-08-14 JP JP2019506623A patent/JP6734469B2/en not_active Expired - Fee Related
- 2017-08-14 SG SG11201900680PA patent/SG11201900680PA/en unknown
- 2017-08-14 PL PL17764658T patent/PL3500306T3/en unknown
- 2017-08-14 PT PT177646585T patent/PT3500306T/en unknown
- 2017-08-14 EP EP17764658.5A patent/EP3500306B1/en active Active
- 2017-08-14 BR BR112019002637A patent/BR112019002637A2/en active Search and Examination
- 2017-08-14 US US16/319,668 patent/US20190336509A1/en not_active Abandoned
- 2017-08-14 MA MA45988A patent/MA45988B1/en unknown
- 2017-08-14 RS RS20201135A patent/RS60832B1/en unknown
- 2017-08-14 LT LTEP17764658.5T patent/LT3500306T/en unknown
- 2017-08-14 EA EA201990481A patent/EA036480B1/en unknown
- 2017-08-14 DK DK17764658.5T patent/DK3500306T3/en active
- 2017-08-14 CA CA3033050A patent/CA3033050C/en active Active
- 2017-08-14 AU AU2017311666A patent/AU2017311666B2/en not_active Ceased
- 2017-08-14 HU HUE17764658A patent/HUE051474T2/en unknown
-
2019
- 2019-01-22 IL IL264405A patent/IL264405B/en active IP Right Grant
- 2019-01-22 ZA ZA2019/00436A patent/ZA201900436B/en unknown
-
2020
- 2020-09-21 HR HRP20201511TT patent/HRP20201511T1/en unknown
- 2020-09-22 CY CY20201100891T patent/CY1123522T1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140135304A1 (en) * | 2011-02-23 | 2014-05-15 | Suven Life Sciences Limited | Novel compounds as histamine h3 receptor ligands |
| WO2014136075A1 (en) * | 2013-03-06 | 2014-09-12 | Richter Gedeon Nyrt. | H3 antagonists containing phenoxypiperidine core structure |
Non-Patent Citations (2)
| Title |
|---|
| KHAN NADIA ET AL, BEHAVIOURAL BRAIN RESEARCH, (2015-10-20), vol. 297, pages 155 - 164 * |
| ZLOMUZICA ARMIN ET AL, NEUROPHARMACOLOGY, (2015-05-27), vol. 106, pages 135 - 145 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262921A (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
| IL262920A (en) | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist | |
| US20190175586A1 (en) | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist | |
| AU2017311666B2 (en) | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and NMDA receptor antagonist | |
| US10603323B2 (en) | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors | |
| NZ750121B2 (en) | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |